Related Experiment Video

Updated: May 9, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

High-Affinity SIRPα Variants Potentiate Antibody Therapy Efficacy

    Cancer Discovery
    |July 13, 2013
    PubMed

    Abstract:

    SIRPα variants with high CD47 affinity enhance the antitumor activity of therapeutic antibodies.

    More Related Videos

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
    09:53

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

    Published on: February 6, 2017

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    Related Experiment Videos

    Last Updated: May 9, 2026

    A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
    11:13

    A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

    Published on: July 12, 2018

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
    09:53

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

    Published on: February 6, 2017

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    Related Concept Videos

    Affinity and Avidity01:41

    Affinity and Avidity

    Overview
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

    Articles linked to this work by shared authors, journal, and citation graph.

    Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

    Cancer discovery·2026

    Microplastics and Cancer: Still Searching for Causation.

    Cancer discovery·2026

    Targeting RAS for Pancreatic Cancer Interception.

    Cancer discovery·2026

    The liver niche accelerates, while the lung niche restrains secondary spread of breast cancer.

    Cancer discovery·2026

    Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.

    Cancer discovery·2026

    Phase III Trials Test First-Line Options in Advanced NSCLC.

    Cancer discovery·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us